Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase

Yun Yen, Bernard Chu, Christina Yen, Jennifer Shih, Bingsen Zhou

研究成果: 雜誌貢獻文章同行評審

5 引文 斯高帕斯(Scopus)

摘要

p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [3H] CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20%-50% lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same C-terminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Interestingly, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2 although the iron content of the two proteins determined by atomic absorption spectrometry was almost the same. Conversely, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, though EPR spectra of the tyrosyl radical in the two proteins were similar. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The differences in susceptibility to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.

原文英語
頁(從 - 到)235-247
頁數13
期刊Advances in Enzyme Regulation
46
發行號1
DOIs
出版狀態已發佈 - 2006
對外發佈

ASJC Scopus subject areas

  • 分子醫學
  • 分子生物學
  • 遺傳學
  • 癌症研究

指紋

深入研究「Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase」主題。共同形成了獨特的指紋。

引用此